- Home
- PGR vs AMGN Comparison
PGR vs AMGN Comparison
Compare PGR & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGR
- AMGN
- Stock Information
- Founded
- PGR 1937
- AMGN 1980
- Country
- PGR United States
- AMGN United States
- Employees
- PGR N/A
- AMGN N/A
- Industry
- PGR Property-Casualty Insurers
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PGR Finance
- AMGN Health Care
- Exchange
- PGR Nasdaq
- AMGN Nasdaq
- Market Cap
- PGR 161.3B
- AMGN 156.2B
- IPO Year
- PGR N/A
- AMGN N/A
- Fundamental
- Price
- PGR $284.90
- AMGN $288.18
- Analyst Decision
- PGR Buy
- AMGN Buy
- Analyst Count
- PGR 16
- AMGN 21
- Target Price
- PGR $287.31
- AMGN $323.62
- AVG Volume (30 Days)
- PGR 2.5M
- AMGN 3.2M
- Earning Date
- PGR 07-15-2025
- AMGN 05-01-2025
- Dividend Yield
- PGR 0.14%
- AMGN 3.30%
- EPS Growth
- PGR 51.82
- AMGN 56.16
- EPS
- PGR 14.83
- AMGN 10.94
- Revenue
- PGR $78,508,000,000.00
- AMGN $34,126,000,000.00
- Revenue This Year
- PGR $15.54
- AMGN $7.62
- Revenue Next Year
- PGR $10.97
- AMGN $1.88
- P/E Ratio
- PGR $19.21
- AMGN $26.34
- Revenue Growth
- PGR 20.74
- AMGN 15.56
- 52 Week Low
- PGR $201.34
- AMGN $253.30
- 52 Week High
- PGR $292.99
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- PGR 56.81
- AMGN 58.41
- Support Level
- PGR $273.42
- AMGN $269.10
- Resistance Level
- PGR $280.44
- AMGN $276.90
- Average True Range (ATR)
- PGR 5.64
- AMGN 5.90
- MACD
- PGR -0.54
- AMGN 2.48
- Stochastic Oscillator
- PGR 73.21
- AMGN 97.70
About PGR Progressive Corporation (The)
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 24 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split roughly equally between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.